Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

3

Revenue 2017

MabThera/Rituxan

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. MabThera/Rituxan was produced by Roche.

The good, the bad and the ugly

The good, the bad and the ugly The main drivers of revenue for Roche are well-established, standard-of-care blockbuster oncology drugs including Rituxan, Herceptin and Avastin. ... Humira remains at the top, but Celgene’s Revlimid has jumped ahead of Roche’s Avastin, MabThera and

NICE backs Roche’s Gazyvaro after initial rejection

NICE backs Roche’s Gazyvaro after initial rejection clinical profile justified premium pricing over Mabthera (rituximab), Roche’s older drug for the FL indication. ... Like MabThera, Gazyvaro targets the CD20 receptor but has been designed with sugar molecule side chains that improve its therapeutic and

Roche faces biosimilar blitz in 2018

Roche faces biosimilar blitz in 2018 Novartis’ unit Sandoz and Celltrion/Mundipharma’s Truxima have also claimed a European approval for its biosimilar versions of Roche’s immunotherapy drug MabThera (rituximab). ... Additionally, Rituxan is expected to plummet by 16% to CHF 6.1bn

Novartis doubles down on biosimilars with Biocon alliance

Novartis doubles down on biosimilars with Biocon alliance In the last couple of years it has picked up approvals for Rixathon - a biosimilar of Roche’s cancer and arthritis drug MabThera (rituximab) - as well as its Erelzi version of

Roche buys cancer company Ignyta for $1.7bn

Roche buys cancer company Ignyta for $1.7bn It has been bolstering its oncology pipeline in particular as three of its top-selling drugs – Avastin, Herceptin and Rituxan – are starting to face biosimilar competition.

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics